1 Mg Anastrozole Tablets IP

Name: 1 Mg Anastrozole Tablets IP
Brand: NEETCO BIOPHARMA
Price: 300 INR
Availability: InStock

Price 300 INR/ Strip

Get a Price/Quote

MOQ : 1 Strip

1 Mg Anastrozole Tablets IP Specification

Dosage Form
Tablet

Indication
Breast Cancer treatment, specifically in postmenopausal women

Salt Composition
Anastrozole 1 mg

Enzyme Types
Aromatase inhibitor

Feature
Highly effective aromatase inhibitor for breast cancer therapy

Ingredients
Anastrozole, Excipients

Application
Oral anti-cancer drug

Physical Color/Texture
White to off-white, film-coated tablet

Enzymatic Activity
Inhibits aromatase enzyme to reduce estrogen formation

Storage Instructions
Store at temperature below 30C, protected from moisture and light

Shelf Life
24 months

About 1 Mg Anastrozole Tablets IP

Unlock phenomenal therapeutic potential with 1 Mg Anastrozole Tablets IP, a peerless and popular choice for managing breast cancer in postmenopausal women. Each box contains 10 film-coated tablets, designed for oral administration and compliant with the Indian Pharmacopoeia (IP) standards. Astonishingly effective, these tablets inhibit the aromatase enzyme to reduce estrogen levels and support targeted cancer therapy. With clear tablet markings for easy splitting and expiry details per regulatory norms, this prescription-only anti-cancer drug from India stands out for its safety, potency, and reliability in clinical use.

How to Use and Key Features

1 Mg Anastrozole Tablets IP is a prescription-only oral anti-cancer medication indicated for postmenopausal breast cancer treatment. Administered by mouth, the tablets may be split easily if marked, ensuring precise dosing. Not for premenopausal women or use in pregnancy, these tablets offer highly effective aromatase inhibition, designed for patient convenience and compliance. Always follow your healthcare provider's directions for optimal results and safety when using this peerless breast cancer therapy.

Order Completion and Export Markets

Order completion is prompt, with shipments dispatched swiftly after processing. 1 Mg Anastrozole Tablets IP can be exported to leading markets in Asia, Africa, and other regions, with sample policies available upon request to demonstrate product quality. Shipped in secure Alu-Alu or blister packaging, orders are fulfilled efficiently, ensuring optimal delivery timelines for distributors, exporters, suppliers, and traders from India, aligning with international pharmaceutical standards.

FAQ's of 1 Mg Anastrozole Tablets IP:

Q: How should 1 Mg Anastrozole Tablets IP be administered for optimal benefit?

A: 1 Mg Anastrozole Tablets IP should be taken orally as prescribed by your physician, following all dosage instructions. Tablet markings may help with splitting for precise dosing. Only postmenopausal women should use this medication.

Q: What are the main indications for using Anastrozole Tablets IP?

A: Anastrozole Tablets IP is mainly indicated for the treatment of breast cancer in postmenopausal women, working as a selective aromatase inhibitor to reduce estrogen formation and support cancer therapy.

Q: When can I expect my order of 1 Mg Anastrozole Tablets IP to be shipped?

A: Orders are completed and shipped promptly once processed, with secure packaging to ensure product integrity during delivery to distributors and exporters worldwide.

Q: Where can I find expiry and registration details for these tablets?

A: Expiry dates and the product's registration number are clearly printed on the strip and carton packaging as per regulatory requirements for easy reference and compliance.

Q: What side effects should I watch for when taking Anastrozole Tablets IP?

A: Common side effects include hot flushes, joint pain, and weakness. It is important to consult your healthcare provider if you experience any adverse reactions while taking this medication.

Q: What is the benefit of inhibiting the aromatase enzyme in breast cancer treatment?

A: By inhibiting the aromatase enzyme, Anastrozole effectively reduces estrogen levels, which is crucial for managing estrogen-sensitive breast cancer in postmenopausal women.

Tell us about your requirement